The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA’ to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
The study looked at 1,364 children in Arizona, Florida, Texas, and Utah who submitted weekly nasal swabs and surveys from July 2021 through February 2022, regardless of whether they had symptoms
Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
100% efficacy against severe Covid-19 disease and hospitalizations
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
he financing was significantly oversubscribed with high demand from both existing and new investors.
Subscribe To Our Newsletter & Stay Updated
